



emyria
(ASX:EMD)

*Creating **tomorrow's** therapies
from **today's patient stories***

Company Update | July 2023

DISCLAIMER

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.


This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Presentation release authorised by Michael Winlo, CEO and Managing Director

EMYRIA'S CAPITAL STRUCTURE

Listed on ASX Feb, 2020

KEY METRICS	VALUE
Market Capitalisation	~A\$42M
Last reported cash (at 31 Mar 2023)	A\$2.2M + R&D \$917k (April) + Placement \$2.5M (April)



OUR GLOBAL VISION | INNOVATIVE CARE & THERAPY DEVELOPMENT

Our robust **CARE DELIVERY**  services, brought to you by



& **PaxCentre**, and are built on a triad of excellence:

Achieving transformative patient outcomes

Generating sustainable revenue streams

Gathering valuable **REAL-WORLD DATA** 

This **virtuous cycle** fuels our

THERAPY DEVELOPMENT 

Creating Ultra-Pure Cannabinoids

Exploring MDMA analogues

Pioneering psychedelic-assisted therapies

**CARE
DELIVERY**



emyria



**REAL -
WORLD
DATA**

**THERAPY
DEVELOPMENT**



Together, these pillars embody Emyria's commitment to **advancing MENTAL HEALTH CARE**

THE PROBLEM | THE RISING COST & BURDEN OF MENTAL HEALTH CARE

The Mental Health Burden in Australia



1 in 5 adults and **1 in 7** young people experienced a mental health disorder in the previous 12 months ¹

4.7 million people (18% of Australians) filled a mental health-related prescription in 2021–22 ¹

\$11.6 billion was spent on mental health services in 2020–21, around 7.3% of the total government health expenditure ¹

BUT... 1 in 3 psychologists have closed books! ²




In 2019, **US spending on mental health treatments surpassed \$225B** ³

THE GAP | SAFE, EFFECTIVE, DURABLE & AFFORDABLE TREATMENTS

Psychedelic-assisted therapy

shows remarkable promise for addressing this gap

67% of participants in the MDMA group no longer met criteria for PTSD two months after the sessions.
(c/w 32% of participants in the placebo group) ¹



REGULATORS ARE CHANGING THEIR STANCE ON MDMA & PSILOCYBIN

EXCITING REGULATORY SHIFT



In a world first, **Australia** has officially recognised **MDMA** and **psilocybin** as controlled medicines from July 1st, 2023.



Australian Government

Department of Health and Aged Care
Therapeutic Goods Administration

GIVING AUSTRALIA AT LEAST A 1 YEAR HEAD START ON REST OF WORLD



SOURCE: 1. Presentation MAPS Psychedelic Symposium, Denver, CO, June 2023

HOWEVER...

MEDICINES ONLY AVAILABLE VIA
AUTHORISED PSYCHIATRISTS FOR SPECIFIC CONDITIONS
OR ***Clinical Trials***

”

*“For approval to prescribe, psychiatrists will need to demonstrate **appropriate training**, patient selection, **evidence-based treatment protocols** and **patient monitoring**. Further, ongoing **psychotherapeutic support remains an essential component** of the psychedelic treatment model.”*




The Royal
Australian &
New Zealand
College of
Psychiatrists

-RANZCP (College of Psychiatrists)

...AND DELIVERY COSTS ARE HIGH DUE TO INTENSIVE THERAPY

Example: MDMA-assisted therapy protocol



CURRENT **PER PATIENT COST**
FOR
3 ROUNDS OF TREATMENT IS
~\$25k

How are we going to **deliver**
psychedelic-assisted therapy
& how will patients **afford** them?



Very few clinical services are currently capable of delivering these therapies.

& We *need* more **evidence**.

WHAT'S NEEDED FOR *AFFORDABLE* PSYCHEDELIC-ASSISTED THERAPY?



(1) THRIVING CLINICAL SERVICE

A vibrant, patient-centric clinical service is crucial for integrating these therapies and gathering data.

We need to build the necessary infrastructure and support systems to incorporate innovative treatments while upholding the highest standards of care.

WHAT'S NEEDED FOR AFFORDABLE PSYCHEDELIC-ASSISTED THERAPY?



(1) THRIVING CLINICAL SERVICE

A vibrant, patient-centric clinical service is crucial for integrating these therapies and gathering data.

We need to build the necessary infrastructure and support systems to incorporate innovative treatments while upholding the highest standards of care.



(2) SKILL WITH EMERGING THERAPIES

The unique and complex nature of psychedelic-assisted therapies demands specific expertise and understanding.

Mastery in managing these intricate treatments—from careful patient selection, to the nuances of therapeutic guidance during sessions, to integration afterwards—is an absolute necessity.

WHAT'S NEEDED FOR AFFORDABLE PSYCHEDELIC-ASSISTED THERAPY?



(1) THRIVING CLINICAL SERVICE

A vibrant, patient-centric clinical service is crucial for integrating these therapies and gathering data.

We need to build the necessary infrastructure and support systems to incorporate innovative treatments while upholding the highest standards of care.



(2) SKILL WITH EMERGING THERAPIES

The unique and complex nature of psychedelic-assisted therapies demands specific expertise and understanding.

Mastery in managing these intricate treatments—from careful patient selection, to the nuances of therapeutic guidance during sessions, to integration afterwards—is an absolute necessity.



(3) ROBUST CLINICAL DATA

To help navigate and solve intricate puzzles relating to dosage, patient response, safety protocols, long-term outcomes and cost benefits we require high-quality, robust data.

Establishing a solid scientific foundation is crucial to instill confidence among professionals, patients, and regulators.

Emyria has done this *before....*

OUR CLINICAL SERVICE EVOLUTION



Australian Government

THC & CBD
legalised
medicines in
Australia ¹

2016



Dec
2018



**Emyria commences drug
development programs:**
novel Ultra-Pure CBD
formulation + proprietary
MDMA analogues ³

2020



ASX

**Emyria establishes
specialist clinics** (Emerald
Clinics) and treats first
patients with THC and CBD
(~10,000 patients treated since ²)



emyria

SOURCES:

1. <https://www.tga.gov.au/news/news/final-decision-scheduling-cannabis-and-tetrahydrocannabinols-frequently-asked-questions#decision>
2. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804653>
3. <https://emyria.com/development-programs/>
4. See ASX release 22 Nov 2021

5. See ASX release 18 Oct 2023

6. See ASX release 04 April 2023

7. <https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin>

OUR ADVANTAGES | A PROVEN TRACK RECORD

A **data-centric** clinical service working with **newly rescheduled treatments** like THC & CBD to monitor & care for patients when ***“nothing else has worked”***



- **GP-led** clinical service
- **~10,000+** patients
- **40+** clinical conditions
- **Cannabinoid-based medicine** specialists
- **World's largest data registry** on cannabinoid-based therapies and outcomes¹
- Leveraging  **Palantir Foundry**²



OUR ADVANTAGES | ROBUST DATA CAPTURE & ANALYSIS CAPABILITIES

We are experienced in **tracking clinical outcomes & personalising care**




% of patients with “moderate” to “severe”
ANXIETY, DEPRESSION, STRESS

TOP 10 indications:	ANXIETY ¹	DEPRESSION ¹	STRESS ¹	INSOMNIA ²
Chronic non-cancer pain	73	52	39	60
Insomnia	76	49	42	95
Cancer pain	75	37	24	75
Anxiety	57	70	73	85
PTSD	42	82	76	95
Autism	68	54	80	77
Depression	76	71	67	83
Migraine/headache	74	44	40	84
Irritable bowel syndrome	62	45	42	85
Parkinson's disease	59	52	43	89

CLINICAL IMPACT EXAMPLE:


Our Cannabinoid-Based Care Model Can Improve Symptoms Of
Psychological Distress Across A Range Of Diagnoses



OUR ADVANTAGES | ROBUST DATA CAPTURE & ANALYSIS CAPABILITIES

We are experienced in **tracking clinical outcomes & personalising care**

CLINICAL IMPACT EXAMPLE: OUR CANNABINOID-BASED CARE MODEL CAN REDUCE OPIOID USE¹



OUR ADVANTAGES | *ACTIVE DRUG DEVELOPMENT & DISCOVERY*

Our data has inspired **multiple drug development & registration** programs

EMD-RX5



An Ultra-Pure CBD capsule for **over-the-counter** treatment of anxiety and stress symptoms.

15% of all adults.¹

In **Phase 3** clinical trials.

Commercialised to Aspen Pharmacare Australia.²

EMD-RX7



High bioavailability Ultra-Pure CBD for **prescription** indications, like opioid-sparing.

Opioid use disorder is a **\$471.0 billion** expense in the US.³

In preclinical screening in USA.

Currently being assessed by the **NIH (USA)** in their Preclinical Screening Program for Pain (PSPP) program.⁴

EMD-RX9



High potency, high bioavailability Ultra-Pure CBD for **prescription** indications.⁵

Market leader: **Epidiolex (\$1B/yr)**⁶

Preparing for Phase 1 clinical trials.

Seeking commercialisation partners.

SOURCES:

1. Australian Institute of Health and Welfare 2018. Australia's health 2018. Australia's health series no. 16. AUS 221.

2. See ASX release 04 April 2023

3. <https://www.cdc.gov/injury/features/health-econ-cost-of-injury/index.html>


4. See ASX release 28 Nov 2022

5. See ASX release 24 April 2023

6. <https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2022>

Emyria is now poised to do the same for
psychedelic-assisted therapies...

OUR CLINICAL SERVICE EVOLUTION



SOURCES:

1. <https://www.tga.gov.au/news/news/final-decision-scheduling-cannabis-and-tetrahydrocannabinols-frequently-asked-questions#decision>
2. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804653>
3. <https://emyria.com/development-programs/>
4. See ASX release 22 Nov 2021

5. <https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin>

OUR CLINICAL SERVICE EVOLUTION

The PAX Centre: Australia's leading **complex psychological trauma treatment**¹

July
2023



- **Psychiatrist**-led service for **complex trauma care**¹
- **Diverse service offering**
- **19 clinicians:** psychiatrists, mental health nurses, psychologists, counsellors, OTs & social workers, physical therapists
- Ethics-approved **psychedelic - assisted therapy model**²


emyria



a unique collaboration to reimagine trauma recovery

OUR CLINICAL SERVICE TRANSFORMATION

Integrated data-centric **Primary & Specialist Care** providing advanced therapies to patients in need to deliver **great patient outcomes, robust data & sustainable revenues**



OUR DELIVERY ADVANTAGE | DATA DRIVEN, MULTIDISCIPLINARY CARE

SERVICE MODEL	KEY STRENGTHS	KEY LIMITATIONS	EMYRIA ADVANTAGES
GP Clinics	Accessible, generalised care	Limited support; not specialised	✓ Our model provides specialised care with <u>robust support</u>
Specialists	High-level, specialised care	Often do not address physical health	✓ Our model offers multidisciplinary care covering <u>mental</u> & <u>physical</u> health
“Single service” clinics (eg. “Ketamine Clinics”)	Specialised service	Referral risk for clinicians. <i>“Where do my patients go if treatment fails?”</i>	✓ Our model offers <u>a suite of services</u> before, during & after care
Academic & Research Centers	Cutting-edge research and treatments	Not focused on scalable, cost effective delivery	✓ Our model combines innovative approaches with <u>scalability</u> and <u>cost effective delivery</u>
EMYRIA MODEL	Multidisciplinary, data-driven, scalable	---	✓ Outperforms other models by delivering comprehensive, data-driven care at scale; + next-generation therapy development

OUR CARE MODEL | A PERSONALISED PATH TO MENTAL WELLNESS

We offer a **suite of solutions & ongoing support**, not just a single service

ACTIVE ASSESSMENT, DATA COLLECTION & REVIEW

Neuropsychiatric disorders share an overlapping imprint of poor body health¹ which is why Emyria's care models prioritise both physical and mental well-being. By providing comprehensive care we can achieve and measure exceptional health outcomes as well as develop new therapies and approaches, **including our own**.

EVIDENCE-BASED CARE



Rapid **intake**
and **assessment**



Evidence-based care led by
psychiatrists & managed by **GPs**
and specially-trained **therapists**


EMERGING TREATMENTS



TMS and / or
Cannabinoid Therapy



Psychedelic-assisted
Therapy



Experimental
Treatments

OUR GROWTH ENGINE | PROFITABLE SERVICES & ROYALTIES

GP + Psychiatrist-led mental health *care*



We provide **comprehensive care**
for **complex neuropsychiatric**
challenges.



- **National care network**
- **30 specialists, GPs & therapists**
- **14,000+ patients treated so far**

OUR GROWTH ENGINE | PROFITABLE SERVICES & ROYALTIES

GP + Psychiatrist-led mental health care



We provide **comprehensive care** for **complex neuropsychiatric** challenges.

- **National care network**
- **30 specialists, GPs & therapists**
- **14,000+ patients treated so far**



Emerging therapy delivery



We facilitate **safe access** to **emerging treatments** and collect **Real-World Data**.

- **Psychedelic-assisted therapies**
- **Cannabinoid medicines**
- **Brain stimulation**

OUR GROWTH ENGINE | PROFITABLE SERVICES & ROYALTIES

GP + Psychiatrist-led mental health care



We provide **comprehensive care** for **complex neuropsychiatric** challenges.

- **National care network**
- **30 specialists, GPs & therapists**
- **14,000+ patients treated so far**



Emerging therapy delivery



We facilitate **safe access** to **emerging treatments** and collect **Real-World Data**.

- **Psychedelic-assisted therapies**
- **Cannabinoid medicines**
- **Brain stimulation**



Proprietary therapy development



We leverage our Real-World Data to create **unique medicines and care models**.

- **Innovative care models**
- **MDMA-inspired medicines**
- **Ultra-Pure CBD medicines**

OUR GROWTH ENGINE | PROFITABLE SERVICES & ROYALTIES

GP + Psychiatrist-led mental health care



We provide **comprehensive care** for **complex neuropsychiatric** challenges.

- **National care network**
- **30 specialists, GPs & therapists**
- **14,000+ patients treated so far**



Emerging therapy delivery



We facilitate **safe access** to **emerging treatments** and collect **Real-World Data**.

- **Psychedelic-assisted therapies**
- **Cannabinoid medicines**
- **Brain stimulation**




Proprietary therapy development



We leverage our Real-World Data to create **robust IP, unique medicines and care models**.

- **Innovative care models**
- **MDMA-inspired medicines**
- **Ultra-Pure CBD medicines**


Clinical Service Revenues



Treatment Royalties

In addition, we are creating opportunities for potential licence revenues from commercialisation partners pending successful registration

EMYRIA IS PREPARED & READY | AN ADVANCED DATA PLATFORM



Data Mastery




Utilising **advanced technologies** like **Palantir Foundry**¹, Emyria efficiently translates clinical insights gathered from *patients we treat* in order to enhance care & therapy development.




Our data has been **published in leading journals, like JAMA**²

Palantir Foundry is AI-ready with in-built Large Language Model (LLM) and AI capabilities.³



EMYRIA IS PREPARED & READY | INNOVATIVE THERAPY DEVELOPMENT



Therapy Innovation

Emyria excels in creating and **managing intricate care models**, including those for newly rescheduled medicines.



Emyria is developing its own deep **pipeline of novel therapies.**

Ultra-Pure Cannabinoids

Novel MDMA analogues

Emerging psychedelic-assisted therapies

EMYRIA IS PREPARED & READY | A COMPREHENSIVE CLINICAL SERVICE



Clinical Services Suite




The Pax Acquisition combines best-in-class conventional care for physical & mental health along with emerging treatments.

Care support from, *GPs, psychiatrists, mental health nurses, counsellors, psychologists, physical therapists, social workers and occupational therapists*

Gathers exceptional **Real-World Data** and generates **sustainable revenues** which, in turn, supports **innovative therapy development**



EMYRIA'S
COMPREHENSIVE
SERVICE



OUR WORLD-CLASS TEAM

World-leaders in **learning health systems**, **mental health** & **therapy development**



Prof Sir John Tooke
FRCP, FMedSci
Clinician-researcher
Expert in learning health systems



Dr Karen Smith
MD, PhD, MBA, LLM
US-based biopharma executive. Multiple FDA approvals



Dr Michael Winlo
MBBS(Hons), MBA
Entrepreneur, big data, clinical trials and drug development



Claire Kullak
BSc (Nursing)
Trauma-specialist and recognised trainer



Dr Jon Laugharne
MBBS, FRCP (UK), FRANZCP
Consultant psychiatrist & therapist



Dr Jenny Morgan
MBBS, FRANZCA
Consultant pain specialist



C/Prof Alistair Vickery
MBBS, FRACGP, FCHSM
Medical Director
Epidemiological researcher



Tracie Ernenwein
BSc, MPH, MHM (Nursing)
Clinical trial specialist
Real-World Data



Dr David Gunn
MBBS, FRACGP
Cannabinoid expert
Substance abuse & mental health treatment



Mary-Ann Rennie
BSc, BCom
Business Development
Clinics Management
GMP manufacturing



Dr Stewart Washer
PhD (Microbiology)
Serial entrepreneur
Multiple ASX listings



Prof Matt Piggott
BSc, PhD (Chemistry)
Specialist in amphetamine chemistry and novel drug design




Matt Callahan
LLB
Patents and litigation
Multiple FDA approvals



Prof Mat-Martin Iverson
Professor, BSc Alta., PhD Br.Col.
Neuropharmacologist
Oxytocin expert

OUR MAJOR ACHIEVEMENTS & NEAR-TERM CATALYSTS



INVEST IN THE FUTURE OF MENTAL HEALTH WITH EMYRIA (ASX: EMD)

A Unique Opportunity in Psychedelic-assisted Therapy

- **Uniquely Positioned:** Based in Australia - where groundbreaking regulatory changes in mental health treatment are occurring - Emyria stands at the forefront of the *psychedelic-assisted therapy revolution* with a model can expand globally:
 - An approved treatment protocol;*
 - A team of trained therapists;*
 - A secured MDMA drug supply;*
 - A facility tailored to these therapies; and*
 - An established data collection and reporting infrastructure that is AI-ready with Palantir's Foundry facilitating vital insights into treatment efficacy and patient care innovation*
- **Proven Track Record:** Our extensive experience with unregistered treatments, mastery of data-driven patient care, and recent acquisition of The Pax Centre solidifies our industry leadership
- **Together, Emyria and The Pax Centre aim to make history** as the first, integrated service to offer psychedelic-assisted therapy in a community practice - care before, during & after treatment - while creating **strong revenues** & generating valuable **clinical data**
- **Multiple therapy development programs**, across Ultra-Pure cannabinoids, MDMA-analogues and psychedelic-assisted therapies - each with large patient populations and market potential





CONTACT INFORMATION

Michael Winlo	mwinlo@emyria.com
Investors	investors@emyria.com
Media	media@emyria.com
General	info@emyria.com

INVESTOR HUB: <https://investorhub.emyria.com/>

APPENDIX:

COMPARE TWO PATIENT JOURNEYS

TODAY'S EXPERIENCE:



Sally is seeking care for mental health symptoms

Books appointment with GP.

GP attempts to refer Sally to a mental health clinician...



...with **1 in 3 providers closed** to new appointments, multiple attempts required.



After a **6 month waitlist** Sally is started on medication.



80% of patients do not respond to antidepressants, neither does Sally. Psychiatrist considers emerging therapies but is unsure where to refer...



...eventually, Sally is referred to treatment center providing a single emerging therapy...

...however, the treatment is not effective.

Sally is now unsure where to go next? Her GP? Her psychiatrist? ED?...



?

EMYRIA'S MODEL

Books appointment with the Emyria team.



Sally is **contacted within 24 hours**. Receives a rapid & comprehensive evaluation. Enrolled in a **multidisciplinary care program** supported by specialists, GPs & allied health clinicians addressing **physical & mental** well being

By remaining in the care model, Sally is regularly reviewed and, if appropriate, provided options like **access emerging therapies** or adjacent programs to reach her health goals



Clinical data generated supports **innovative treatment development**



OUR CARE LANDSCAPE | NEUROPSYCHIATRIC DISORDERS

We are focussed on **Five Major** global physical & mental health conditions:

Complex Trauma

3.6% of US adults
USD\$70 billion ¹

Depression

8.4% of US adults
USD\$210 billion ²

Anxiety

19.1% of US adults
USD\$42 billion ³

Chronic Pain

11.2% of US adults
USD\$635 billion ⁴

Parkinson's Disease

~1M US adults
USD\$51.9 billion ⁵

SOURCES:

1. <https://www.nimh.nih.gov/health/statistics/post-traumatic-stress-disorder-ptsd>

2. <https://www.nimh.nih.gov/health/statistics/major-depression>

3. <https://www.nimh.nih.gov/health/statistics/any-anxiety-disorder>

4. Rikard SM, et al. Chronic Pain Among Adults — United States, 2019–2021

5. Yang, W., et al. Current and projected future economic burden of Parkinson's disease in the U.S.. npj Parkinson's Dis. 6, 15 (2020). <https://doi.org/10.1038/s41531-020-0117-1>

6. www.phoenixaustralia.org/research/research-publications/

7. <https://www.aihw.gov.au/mental-health/overview/mental-illness>

8. National Study of Mental Health and Wellbeing 2020-21 series, Australian Bureau of Statistics

9. <https://shakeitup.org.au/understanding-parkinsons>

10. <https://www.aihw.gov.au/mental-health>

OUR INNOVATIVE THERAPY PIPELINE

Harnessing **Real-World Data** to develop **impactful therapies**

PROGRAM	DEVELOPMENT GOAL	STAGE	COMMERCIAL STATUS	CATEGORY LEADER
Ultra-Pure CBD capsules <i>Highly bioavailable CBD</i>				
EMD-RX5	Pharmacy treatment for mild anxiety & stress	Active Phase 3 clinical trials	Partnered with ASPEN PHARMACARE AUSTRALIA ¹	N/A
EMD-RX7/9	Prescription medicines for complex pain & anxiety	Preparing Phase 1 & Pre-IND Partnered with NIH ²	Pursuing partners	Epidiolex (\$1B/yr) ³
Novel, MDMA-inspired medicines <i>Developed with the University of Western Australia</i>				
EMD-MX1	Faster-acting MDMA to reduce therapy times			Kinosis (Preclinical offer \$273M) ⁴
EMD-MX2	Adjunct treatment for Parkinson's disease	Preclinical screening	Pursuing partners	Levodopa (\$8B /yr) ⁵
EMD-MX3	Other non-neurological indications			Ofev (\$5B/yr) ⁶
Medicine-assisted care programs				
MDMA-AT	MDMA-assisted therapy for PTSD	Active trial	Developing proprietary models for license to other clinicians	MAPS (<i>raised US\$140M to date</i>) ⁷
Psilocybin-AT	Psilocybin-assisted therapy for depression	Care model in development		Compass Pathways (Market Cap \$560M) ⁸

SOURCES:

1. See ASX release 04 April 2023

2. See ASX release 28 Nov 2022

3. <https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2022>

4. <https://www.sydney.edu.au/news-opinion/news/2023/05/05/sydney-spinout-kinosis-273m-developed-by-Pathfinders.html>

5. <https://www.gminsights.com/pressrelease/parkinsons-disease-therapeutics-market>

6. <https://www.boehringer-ingelheim.com>

7. <https://www.lucid.news/strategy-maps-turns-equity-investment/>

8. <https://finance.yahoo.com/quote/CMPS/>

OUR ULTRA-PURE CANNABINOID DRUG DEVELOPMENT

Real-World Data is accelerating the registration of unique **cannabinoid medicines**



Real-World Data

We've treated thousands of diverse patients at Emerald Clinics and gathered one of the largest Real-World Data registries, globally.

We've published in some of the most respected journals in the world.¹ Insights guide our formulations and trial designs.



Ultra-Pure CBD

Lab-created, low-cost, high-purity CBD in patient-preferred dose forms.

Registration

Our drug development programs are targeting registration with the TGA and FDA



EMD-RX5



An Ultra-Pure CBD capsule for **over-the-counter** treatment of anxiety and stress symptoms.

In **Phase 3** clinical trials.

Commercialised to Aspen Pharmacare Australia.¹



EMD-RX7



High bioavailability Ultra-Pure CBD for **prescription** indications.

In preclinical screening in USA.

Currently being assessed by the **NIH (USA)** in their Preclinical Screening Program for Pain (PSP) program.²

EMD-RX9



High potency, high bioavailability Ultra-Pure CBD for **prescription** indications.³

Preparing for Phase 1 clinical trials.


Seeking commercialisation partners.

SOURCES:


1. Arkell TR, Downey LA, Hayley AC, Roth S. Assessment of Medical Cannabis and Health-Related Quality of Life. JAMA Netw Open. 2023;6(5):e2312522. doi:10.1001/jamanetworkopen.2023.12522
2. See ASX release 04 April 2023
3. See ASX release 28 Nov 2022
4. See ASX release 24 April 2023

OUR MDMA-INSPIRED DRUG DISCOVERY

One of the **world's largest libraries of MDMA analogues** developed



MDMA as inspiration



Screened for
selective
modulation of major
neurotransmitters

Dopamine

associated with feelings of *pleasure and satisfaction*

Serotonin


thought to contribute to feelings of *well-being*

Noradrenaline

affects attention and related to "*fight or flight*" response

EMD-MX1


Increasing versatility
of drug-assisted
therapy for mental
health disorders



We have created MDMA-like molecules
with rapid and extended half-lives.

EMD-MX2


Selective serotonin &
dopamine releasers to
help treat Parkinson's.



We have created novel molecules that
extend the symptom relief time of L-DOPA.

EMD-MX3

Highly specific
transporter binding
molecules for range
of indications.



We have novel molecules that are potent
antagonists of 5HT2B, involved in fibrosis.

OUR PSYCHEDELIC-ASSISTED THERAPY PROGRAMS

Unique care models for scalable, integrated delivery

EMDMA-001 MDMA-assisted therapy for Post-Traumatic Stress Disorder (PTSD)

Care model
developed



Drug supply
secured



Therapist training
completed



Ethics
approval



Treatment *about to start*



EMDPsi-001 Psilocybin-assisted therapy for Treatment Resistant Depression (tr-Dep)

Care model
in development



Drug supply
Being procured



Therapist training
completed



Ethics
approval



Treatment *about to start*



PALANTIR FOUNDRY

AIP Features



AI-Optimized Data Foundation

Run LLMs and other AI on a secure, real-time, multi-modal foundation.



AIP Assist

Build everything from pipelines to applications faster, with human-AI collaboration.



AIP Logic

Author no-code functions that use LLMs. Manage, chain and wield those functions in custom applications.



Agents

Define LLM agents to pursue specific, scoped goals.



Action Graph

Implement decisions across your underlying operational systems.



AIP Automate

Monitor the activity of AI agents in real-time, with fine-grain control over both user-approved and autonomous tasks.



Control Panel

Monitor, govern, and control the activity and reach of LLMs and other AI in real-time.



Safe AI Handoff

Connect LLMs to trusted models across your enterprise with safe handoff functions.



Digital Footprint

Audit the full trail of all AI prompts, outputs, explanations, recommendations, and actions.



Human-in-the-Loop

Dictate when decisions require human input, including multi-stakeholder checks.



Decision Capture & Learning

Capture decisions and outcomes for continuous AI validation and improvement.